To contribute to the elimination of schistosomiasis by addressing the medical need of infected preschool-aged children, including infants and toddlers, a group currently devoid of a suitable treatment.



To develop and provide a suitable pediatric praziquantel formulation with acceptable palatability, proven efficacy and safety for treating schistosomiasis in preschool-aged children.



To make a meaningful contribution to tropical medicine and health innovation in endemic countries. We aim to provide scientific evidence and potentially trigger the creation of policies for prevention and treatment of schistosomiasis in children.


Pediatric Praziquantel Formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation consists of small, orodispersible tablets with an (improved) acceptable taste.


Contact us

Thank you for your interest in learning more about the Pediatric Praziquantel Consortium.

We care about your questions and concerns.


Consortium on Stage at GHIT Annual Partners Meeting

On June 7, 2016, the GHIT Fund held its third Annual Partners Meeting to discuss the impact of the fund on the ground. Read more

First patient dosed in Phase II clinical trial

16 June 2016 - Today, the Pediatric Praziquantel Consortium announced that the first patient in a Phase II pediatric clinical trial being conducted in the Ivory Coast has been dosed. Read more

Download our Factsheet here

Video credit: Shelly Xie